DOJ's $12,396 FY26 Adempas Purchase from Bayer Healthcare for 90-ct Bottles
Contract Overview
Contract Amount: $12,396 ($12.4K)
Contractor: Bayer Healthcare Pharmaceuticals Inc
Awarding Agency: Department of Justice
Start Date: 2026-04-01
End Date: 2026-04-30
Contract Duration: 29 days
Daily Burn Rate: $427/day
Competition Type: FULL AND OPEN COMPETITION
Number of Offers Received: 1
Pricing Type: FIRM FIXED PRICE
Sector: Healthcare
Official Description: FY26 APRIL ADEMPAS BAYER/CURASCRIPT ADEMPAS- 1MG TAB-90CT. BOTTLE APRIL FY26- $12,396.11
Place of Performance
Location: WHIPPANY, MORRIS County, NEW JERSEY, 07981
Plain-Language Summary
Department of Justice obligated $12,396.11 to BAYER HEALTHCARE PHARMACEUTICALS INC for work described as: FY26 APRIL ADEMPAS BAYER/CURASCRIPT ADEMPAS- 1MG TAB-90CT. BOTTLE APRIL FY26- $12,396.11 Key points: 1. This purchase of Adempas, a medication for pulmonary hypertension, highlights spending in the pharmaceutical sector for correctional facilities. 2. Bayer Healthcare Pharmaceuticals Inc. is the sole manufacturer listed, indicating potential reliance on a single supplier. 3. The contract is a Firm Fixed Price delivery order, providing cost certainty for this specific purchase. 4. The spending is relatively small in the context of overall federal pharmaceutical procurement.
Value Assessment
Rating: good
The price of $12,396.11 for 90-count bottles of Adempas appears reasonable given the specialized nature of the drug and the quantities involved. Benchmarking against similar federal contracts for high-cost pharmaceuticals would provide a more definitive assessment.
Cost Per Unit: N/A
Competition Analysis
Competition Level: full-and-open
The contract was awarded under full and open competition, suggesting that multiple vendors had the opportunity to bid. This method generally promotes competitive pricing and ensures the government receives fair market value.
Taxpayer Impact: The taxpayer impact is minimal for this specific, relatively small purchase, but contributes to the overall federal healthcare budget.
Public Impact
Ensures access to critical medication for inmates within the Federal Prison System. Supports the operational needs of the Bureau of Prisons in managing inmate health. Reflects the government's commitment to providing necessary medical treatments.
Waste & Efficiency Indicators
Waste Risk Score: 100 / 10
Warning Flags
- Potential for price increases in future procurements if competition diminishes.
- Reliance on a single manufacturer for a critical medication.
Positive Signals
- Firm Fixed Price contract provides budget predictability.
- Awarded under full and open competition.
Sector Analysis
This procurement falls within the pharmaceutical manufacturing sector, specifically for specialized medications used in healthcare settings. Federal spending in this area is substantial, driven by the healthcare needs of various agencies, including correctional facilities.
Small Business Impact
There is no indication that small businesses were involved in this specific contract, as it appears to be awarded to a large pharmaceutical manufacturer.
Oversight & Accountability
The Department of Justice's Bureau of Prisons is responsible for overseeing this contract. Standard procurement regulations and oversight mechanisms should ensure proper execution and accountability.
Related Government Programs
- Pharmaceutical Preparation Manufacturing
- Department of Justice Contracting
- Federal Prison System / Bureau of Prisons Programs
Risk Flags
- Sole manufacturer listed.
- Potential for price escalation in future.
- Limited visibility into long-term supply chain resilience.
Tags
pharmaceutical-preparation-manufacturing, department-of-justice, nj, delivery-order, under-100k
Frequently Asked Questions
What is this federal contract paying for?
Department of Justice awarded $12,396.11 to BAYER HEALTHCARE PHARMACEUTICALS INC. FY26 APRIL ADEMPAS BAYER/CURASCRIPT ADEMPAS- 1MG TAB-90CT. BOTTLE APRIL FY26- $12,396.11
Who is the contractor on this award?
The obligated recipient is BAYER HEALTHCARE PHARMACEUTICALS INC.
Which agency awarded this contract?
Awarding agency: Department of Justice (Federal Prison System / Bureau of Prisons).
What is the total obligated amount?
The obligated amount is $12,396.11.
What is the period of performance?
Start: 2026-04-01. End: 2026-04-30.
What is the long-term strategy for ensuring a stable supply and competitive pricing for Adempas, given its specialized nature?
The long-term strategy should involve monitoring the market for potential new entrants or alternative treatments. Exploring options like multi-year contracts with price negotiation clauses or encouraging generic development, if applicable, could also secure supply and manage costs effectively. Regular market research and engagement with manufacturers are crucial.
What are the risks associated with relying on a single supplier for a critical medication like Adempas?
Reliance on a single supplier poses risks of supply chain disruptions due to manufacturing issues, natural disasters, or geopolitical events. It can also lead to reduced negotiating power for the government, potentially resulting in higher prices over time. Ensuring adequate inventory levels and exploring backup supplier options are mitigation strategies.
How does the Bureau of Prisons assess the effectiveness and necessity of specific high-cost medications like Adempas for inmate populations?
The Bureau of Prisons likely relies on clinical guidelines, expert medical reviews, and formulary management processes to assess the necessity of medications. Effectiveness is typically monitored through patient outcomes and physician evaluations. This ensures that expensive treatments are prescribed appropriately and provide tangible health benefits to inmates.
Industry Classification
NAICS: Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing
Product/Service Code: MEDICAL SERVICES › MEDICAL, DENTAL, AND SURGICAL SVCS
Competition & Pricing
Extent Competed: FULL AND OPEN COMPETITION
Solicitation Procedures: SUBJECT TO MULTIPLE AWARD FAIR OPPORTUNITY
Offers Received: 1
Pricing Type: FIRM FIXED PRICE (J)
Evaluated Preference: NONE
Contractor Details
Parent Company: Bayer AG
Address: 100 BAYER BLVD, WHIPPANY, NJ, 07981
Business Categories: Category Business, Corporate Entity Not Tax Exempt, Foreign Owned, Not Designated a Small Business, Special Designations
Financial Breakdown
Contract Ceiling: $12,396
Exercised Options: $12,396
Current Obligation: $12,396
Contract Characteristics
Commercial Item: COMMERCIAL PRODUCTS/SERVICES
Parent Contract
Parent Award PIID: 36F79720D0237
IDV Type: FSS
Timeline
Start Date: 2026-04-01
Current End Date: 2026-04-30
Potential End Date: 2026-04-30 00:00:00
Last Modified: 2026-04-07
More Contracts from Bayer Healthcare Pharmaceuticals Inc
- Purchase Ciprofloxacin 250mg/5ml Oral Suspension, Powder, 100ML Bottle — $15.1M (Department of Health and Human Services)
View all Bayer Healthcare Pharmaceuticals Inc federal contracts →
Other Department of Justice Contracts
- Contractor Owned and Operated Existing Correctional Facility for Approximately 3,500 LOW Security Male Inmates — $794.5M (Cornell Companies, Inc.)
- Detention Services - SAN Diego — $776.9M (THE GEO Group, Inc.)
- CO: Telly Renfroe Award of NEW Task Order Base Year Initial Funding — $616.4M (AT&T Enterprises, LLC)
- TAS 151060 - Services for the Management and Operation of a Contractor-Owned, Contractor-Operated, Correctional Facility for 2,567 Beds in Adams County, Mississippi — $574.3M (Corecivic, Inc.)
- Provide Services for the Management and Operation of a Correctional Facility in Accordance With Rfp-Pcc-0014 — $568.9M (Cornell Companies, Inc.)